Original BioMedicals Signs Commissioned Service Agreement with OP NANOPHARMA Co., Ltd. for OBM-B01 Cyanide Compound Drug Project (Patent: Composition for Upper Respiratory Tract Administration and Its Administration Method)
Important News
The OBM-B01 cyanide compound lyophilized formulation, developed and manufactured by OP NANOPHARMA Co., Ltd. under our company’s commission, will be used for New Drug Application (NDA) and drug registration. It is expected to bring positive benefits to our company’s financial performance and business operations.
Prev
Human Clinical Trial Plan for Original BioMedicals B01 Cyanide Compound Drug (Patent: Composition for Upper Respiratory Tract Administration and Method) Has Been Approved by the Joint IRB of Taipei Medical University and Its Affiliated Hospital.
Original BioMedicals Has Received Patent Approval from the Intellectual Property Office, Ministry of Economic Affairs (Taiwan), for ‘Chelated Composite Micelles with Antibacterial Activity Against Gram-Negative Bacteria and Their Applications.
